Substituted piperidines as CCR3 antagonists

USRE45323E1 · kind E1 · reissue

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Marc Grundl · Biberach an der Riß, DE
• Horst Dollinger · Schemmerhofen, DE
• Riccardo Giovannini · Verona, IT
• Christoph Hoenke · Ingelheim am Rhein, DE
• Matthias Hoffmann · Mittelbiberach, DE
• Jan Kriegl · Ulm, DE
• Domnic Martyres · Biberach, DE
• Georg Rast · Singen, DE
• Peter Seither · Biberach an der Riß, DE

Key dates

• Filing date: Feb 7, 2014
• Grant date: Jan 6, 2015
• Expiry date: Feb 7, 2034

Classification

• Technology area (CPC —): General

Abstract

Object of the present invention are novel substituted compounds of the formula 1,wherein A, R1, R2, R3 and R4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.